Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Planchard on Dabrafenib/Trametinib Combo in Advanced NSCLC

June 15th 2016

David Planchard, MD, PhD, Department of Medical Oncology, Thoracic Unit, Institut Gustave Roussy, discusses a phase II trial examining the combination of dabrafenib and trametinib in pretreated patients with BRAF V600E-mutant advanced non–small cell lung cancer (NSCLC).

Osimertinib Demonstrates Early Efficacy for Leptomeningeal Disease in NSCLC

June 14th 2016

Phase I findings of a study examining the efficacy of osimertinib (Tagrisso) in heavily pretreated patients with EGFR-mutated advanced non-small cell lung cancer and leptomeningeal disease showed promising activity in the patient population.

Expert Discusses 2-Year Nivolumab Data and Other Immunotherapy Developments in NSCLC

June 10th 2016

Hossein Borghaei, DO, discusses the significance of the 2-year follow-up results of the CheckMate-057 and -017 studies, the evolving role of PD-L1 as a biomarker and others that are in development, and emerging immunotherapy agents in the field of non-small cell lung cancer.

Dr. Melissa Johnson on Atezolizumab in Patients With NSCLC

June 10th 2016

Melissa Johnson, MD, associate director, Lung Cancer Research, Sarah Cannon Research Institute, discusses the phase II BIRCH study, which is examining atezolizumab (Tecentriq) in patients with PD-L1–positive locally advanced or metastatic non–small cell lung cancer (NSCLC).

Bevacizumab/Erlotinib Combo Approved in Europe for NSCLC

June 8th 2016

The European Commission approved bevacizumab in combination with erlotinib as a frontline treatment for patients with unresectable advanced, metastatic, or recurrent EGFR-mutant non–small cell lung cancer.

Alectinib Could Represent First-Line Standard in ALK-Positive NSCLC

June 7th 2016

Alectinib improved progression-free survival by 66% compared with the current standard crizotinib as initial inhibitor therapy in patients with advanced or recurrent ALK-positive non–small cell lung cancer.

PD-L1 Inhibitor Avelumab Active in Advanced Mesothelioma

June 7th 2016

Avelumab demonstrated clinical activity in patients with advanced or unresectable mesothelioma, with an overall response rate of 14.3%.

Web App Boosts Survival for Lung Cancer Patients

June 6th 2016

Patients with lung cancer who participated in a web-based system for reporting and tracking their symptoms achieved dramatic gains in survival compared with individuals who were followed with typical protocols.

Dabrafenib/Trametinib Combo Highly Effective in BRAF-Mutant NSCLC

June 6th 2016

The combination of dabrafenib and trametinib was highly effective as a treatment for patients with BRAF V600E-mutant non–small cell lung cancer.

Rovalpituzumab Tesirine Shows Promising Efficacy for SCLC

June 6th 2016

Treatment with rovalpituzumab tesirine demonstrated single-agent activity and a manageable safety profile for patients with recurrent/refractory small cell lung cancer.

Nivolumab/Ipilimumab Frontline Response Nears 60% in PD-L1+ NSCLC

June 5th 2016

Upfront treatment with the combination of nivolumab and ipilimumab demonstrated an objective response rate of 57% in patients with PD-L1-positive advanced non–small cell lung cancer.

Nivolumab Survival Benefit Sustained in Long-Term NSCLC Outcomes

June 5th 2016

Two-year follow-up data showed sustained improvements in overall survival with nivolumab in pretreated patients with either nonsquamous or squamous non–small cell lung cancer in updated findings from the phase III CheckMate-057 and -017 trials.

Nivolumab/Ipilimumab Combination Active in Recurrent SCLC

June 4th 2016

Treatment with the combination of nivolumab and ipilimumab demonstrated a median overall survival of 7.7 months and a 1-year OS rate of 43% for patients with recurrent small cell lung cancer.

Dr. Borghaei on 2-Year Findings With Nivolumab Vs Docetaxel in NSCLC

June 4th 2016

Hossein Borghaei, DO, chief, Thoracic Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses 2-year follow-up results of the CheckMate-017 and -057 studies, which compared the efficacy of nivolumab (Opdivo) versus docetaxel in patients with advanced non–small cell lung cancer (NSCLC).

Everolimus Approved in Europe for GI, Lung NETS

June 2nd 2016

The European Commission has approved everolimus (Afinitor) for use as treatment for patients with progressive, unresectable or metastatic, well-differentiated nonfunctional gastrointestinal or lung neuroendocrine tumors.

FDA Approves Novel Diagnostics for NSCLC, NETs

June 2nd 2016

The FDA has approved new diagnostic tests for the detection of somatostatin receptor-positive neuroendocrine tumors and for EGFR mutations from blood samples for patients with non–small cell lung cancer.

Dr. Keith Keer on PD-L1 in Lung Cancer

May 26th 2016

Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the University of Aberdeen, Aberdeen, Scotland, discusses PD-L1 immunohistochemistry in lung cancer.

IHC Staining Found Effective for ROS1+ NSCLC

May 22nd 2016

The use of immunohistochemistry could be a more cost- and time-efficient first-line screening method for identifying ROS1 gene rearrangements to predict eligibility for crizotinib (Xalkori) for patients with non–small cell lung cancer compared with fluorescence in-situ hybridization.

Expert Discusses Promise of CRS-207 Vaccine in Mesothelioma

May 16th 2016

Thierry M. Jahan, MD, discusses a study looking at the investigational cancer vaccine CRS-207 and its potential in mesothelioma.

Further Steps Needed to Unleash Full Potential of Immunotherapy in Lung Cancer

May 13th 2016

John Haanen, MD, PhD, discusses why the best combination regimens and the ideal patient population for immunotherapy treatments in lung cancer are still largely unknown.